ANI Pharmaceuticals Dirección
Dirección controles de criterios 2/4
El CEO de ANI Pharmaceuticals es Nikhil Lalwani , nombrado en Sep 2020, tiene una permanencia de 4.17 años. compensación anual total es $8.08M, compuesta por 9.5% salario y 90.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.91% de las acciones de la empresa, por valor de $21.63M. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 4.2 años, respectivamente.
Información clave
Nikhil Lalwani
Chief Executive Officer (CEO)
US$8.1m
Compensación total
| Porcentaje del salario del CEO | 9.5% |
| Permanencia del CEO | 4.2yrs |
| Participación del CEO | 1.9% |
| Permanencia media de la dirección | 3yrs |
| Promedio de permanencia en la Junta Directiva | 4.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly
Nov 09
ANI Pharmaceuticals Is Acting Like It Is Being Acquired
Nov 02ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market
Oct 11There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues
Sep 10ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem
Aug 14Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Aug 08ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
Aug 02Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price
Jun 10ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
Jun 10These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well
Feb 17Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings
Nov 15Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Sep 22Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Feb 22We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt
Oct 28ANI Pharma launches generic Prochlorperazine maleate tablets
Aug 29ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval
Aug 16Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$9m |
| Jun 30 2024 | n/a | n/a | US$24m |
| Mar 31 2024 | n/a | n/a | US$31m |
| Dec 31 2023 | US$8m | US$764k | US$15m |
| Sep 30 2023 | n/a | n/a | US$10m |
| Jun 30 2023 | n/a | n/a | -US$8m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$5m | US$737k | -US$50m |
| Sep 30 2022 | n/a | n/a | -US$69m |
| Jun 30 2022 | n/a | n/a | -US$65m |
| Mar 31 2022 | n/a | n/a | -US$63m |
| Dec 31 2021 | US$7m | US$715k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$22m |
| Jun 30 2021 | n/a | n/a | -US$17m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$4m | US$199k | -US$23m |
Compensación vs. Mercado: La compensación total de Nikhil($USD8.08M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.15M).
Compensación vs. Ingresos: La compensación de Nikhil ha aumentado mientras la empresa no es rentable.
CEO
Nikhil Lalwani (46 yo)
4.2yrs
Permanencia
US$8,078,353
Compensación
Mr. Nikhil Lalwani served as a Director of Association for Accessible Medicines. He served as the Chief Executive Officer of InvaGen Pharmaceuticals, Inc. since October 24, 2016. Mr. Lalwani is a seasoned...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.2yrs | US$8.08m | 1.91% $ 21.6m | |
| Senior VP of Finance & CFO | 8.5yrs | US$2.58m | 0.83% $ 9.4m | |
| Senior Vice President of Corporate Development & Strategy | 3yrs | US$1.90m | 1.24% $ 14.1m | |
| Senior Vp & Head of Rare Disease | 3.8yrs | US$1.91m | 0.39% $ 4.4m | |
| Senior Vice President of Generics | 3.8yrs | US$1.94m | 0.40% $ 4.5m | |
| Head of R&D | 3yrs | sin datos | 0.26% $ 3.0m | |
| Senior Vice President of Operations | 8.5yrs | US$1.43m | 0.60% $ 6.8m | |
| Chief Compliance Officer & Head of Legal of Rare Disease | 2.8yrs | sin datos | sin datos | |
| Senior VP | 2.3yrs | sin datos | 0.29% $ 3.3m | |
| Senior VP & Chief Human Resources Officer | 2.2yrs | sin datos | 0.26% $ 2.9m | |
| Chief Medical Officer | 2.8yrs | sin datos | sin datos | |
| Senior VP & Head of Established Brands | 3yrs | sin datos | 0.17% $ 1.9m |
3.0yrs
Permanencia media
51.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ANIP se considera experimentado (3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.2yrs | US$8.08m | 1.91% $ 21.6m | |
| Head of R&D | 3yrs | sin datos | 0.26% $ 3.0m | |
| Independent Chairman | 6.5yrs | US$422.21k | 0.38% $ 4.3m | |
| Independent Director | 4.3yrs | US$393.25k | 0.16% $ 1.8m | |
| Independent Director | 6.5yrs | US$412.21k | 0.26% $ 3.0m | |
| Independent Director | 4.3yrs | US$395.75k | 0.21% $ 2.3m | |
| Independent Director | 2.7yrs | US$392.37k | 0.12% $ 1.3m | |
| Independent Director | 1.3yrs | US$470.76k | 0.061% $ 693.9k |
4.2yrs
Permanencia media
61.5yo
Promedio de edad
Junta con experiencia: La junta directiva de ANIP se considera experimentada (4.2 años de antigüedad promedio).